Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNAF), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics Corp (MDNAF) is a clinical-stage biopharmaceutical company advancing targeted cytokine therapies for cancer and immune disorders. This news hub provides investors and researchers with verified updates on the company’s therapeutic developments, strategic partnerships, and clinical progress.
Access real-time announcements about MDNAF’s innovative immunotherapy pipeline, including updates on superkine engineering, empowered cytokine platforms, and trial milestones. The repository consolidates essential documents such as earnings reports, regulatory filings, and scientific presentations, offering a comprehensive view of corporate and research activities.
Key content categories include clinical trial advancements, intellectual property updates, executive leadership changes, and collaborative research initiatives. All materials are sourced directly from company communications to ensure accuracy and compliance with disclosure standards.
Bookmark this page for streamlined access to Medicenna’s latest developments in precision immunotherapy. Check regularly for updates on novel therapeutic candidates designed to address unmet needs in oncology through selective cytokine modulation.
Medicenna Therapeutics announced that Dr. Fahar Merchant, its President and CEO, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 10:00 AM ET. The presentation will provide an overview of the company's immuno-oncology developments, including its promising MDNA11 and MDNA55 assets, focused on cancer treatment. A live webcast will be accessible here. A replay will be available post-event on Medicenna's website.
Medicenna Therapeutics Corp. (NASDAQ: MDNA; TSX: MDNA) announced promising preclinical data for MDNA19-MDNA413, a dual-specific cytokine developed from their BiSKITs™ platform, presented at the AACR Annual Meeting. This innovative therapy selectively activates anti-cancer immune cells while inhibiting pro-tumoral macrophage polarization. Key findings highlighted a 209-fold and 90-fold enhancement in CD8/Treg and NK/Treg ratios, respectively, and effective suppression of IL-13 induced M2a macrophage polarization. Medicenna plans to advance its development and regulatory submissions for MDNA11, another promising superkine therapy.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced the presentation of an abstract during the AACR Annual Meeting 2021 on April 10-15, highlighting early preclinical studies of a novel bispecific Superkine. The abstract, titled Modulation of Immune Responses to Cancer by Bi-specific IL-2/IL-13 Superkines, focuses on an innovative approach combining IL-2 super-agonist with IL-4/IL-13 super-antagonist. The full abstract is available on AACR's website and will be accessible on Medicenna's site post-conference.
Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) announced that Dr. Fahar Merchant, CEO, will present at multiple investor conferences in March 2021. These include the H.C. Wainwright Global Life Sciences Conference, with a pre-recorded presentation available on-demand from March 9, and the Oppenheimer 31st Annual Healthcare Conference, featuring a live presentation on March 17. Additionally, Dr. Merchant will participate in a live panel discussion at the Maxim 2021 Emerging Growth Virtual Conference on the same day. Details for accessing the webcasts are available on Medicenna's Investor Relations website.
Medicenna Therapeutics Corp. (NASDAQ: MDNA; TSX: MDNA) announced that CEO Dr. Fahar Merchant will present a corporate overview at the 41st Annual Cowen Healthcare Conference on March 2, 2021, at 2:10 PM ET. Interested parties can access a live webcast here. The presentation replay will be available on Medicenna's Investor Relations page. The company focuses on immunotherapy with assets like MDNA11 and MDNA55, targeting various cancers and has obtained Fast-Track designation from the FDA.
FAQ
What is the current stock price of Medicenna Therapeutics (MDNAF)?
What is the market cap of Medicenna Therapeutics (MDNAF)?
